Clinical trials: Mild to Moderate Alzheimer's Disease
Alzheimer's Disease
European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients
The purpose of this Phase 3 study is to evaluate the efficacy and safety of 3APS as an add-on therapy to most standard medication for Alzheimer's disease compared to placebo (inactive substance pill) in patients with mild to…
- Trial name
- NCT00217763
- Testing
- 3APS
- Where
- 69 sites in Belgium, France and 8 more
- Volunteers
- 930 people
- Sponsor
- Bellus Health Inc. - a GSK company
Alzheimer's Disease
Safety Study of MT-4666 in Subjects With Alzheimer's Disease
The objective of this study is to evaluate the safety and efficacy of 2 fixed dose of MT-4666 administered once daily for 52 weeks with or without receiving a concomitant acetylcholinesterase inhibitors (AChEIs), in patients with…
- Trial name
- NCT02327182
- Testing
- MT-4666
- Where
- Japan
- Volunteers
- 117 people
- Sponsor
- Tanabe Pharma Corporation
Alzheimer Disease
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 weeks.
- Trial name
- REFOCUS-ALZ (NCT05026177)
- Testing
- Simufilam
- Where
- 89 sites in United States, Canada and 2 more
- Volunteers
- 1,125 people
- Sponsor
- Cassava Sciences, Inc.
Chronic Insomnia
Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine the efficacy of ramelteon, once daily (QD), in subjects with mild to moderate Alzheimer's Disease and sleep disturbance
- Trial name
- NCT00325728
- Testing
- Ramelteon
- Where
- 72 sites in United States
- Volunteers
- 74 people
- Sponsor
- Takeda
Cognitive Impairments, Alzheimer Disease
Study to Evaluate the Effect of a Vegetal Oil on Cognitive Impairment
The aim of the study is to evaluate the beneficial effect of a mixture of vegetal oils with a composition related to short, medium and long unsaturated chain fatty acids on patients with a diagnose of cognitive impairment or mild…
- Trial name
- NCT02778581
- Testing
- Lipidic Blend 1, Lipidic Blend 2
- Where
- 2 sites in Spain
- Volunteers
- 110 people
- Sponsor
- Team Foods Colombia S.A.
Alzheimer's Disease
Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients
To conduct a proof of concept study in patients with mild to moderate Alzheimer's Disease in order to determine if there is less global brain atrophy over one year, as measured by ventricular enlargement as a primary outcome…
- Trial name
- SARTAN-AD (NCT02085265)
- Testing
- Perindopril, Telmisartan
- Where
- 10 sites in Canada
- Volunteers
- 23 people
- Sponsor
- Sunnybrook Health Sciences Centre
Alzheimer Disease
Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease
The purpose of the study is to evaluate the safety and tolerability of multiple doses of NPT088 in patients with mild to moderate probable Alzheimer's Disease.
- Trial name
- NCT03008161
- Testing
- NPT088
- Where
- 23 sites in United States
- Volunteers
- 83 people
- Sponsor
- Proclara Biosciences, Inc.
Alzheimer's Disease
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer's Disease.
- Trial name
- NCT01689246
- Testing
- TRx0237 150 mg/day, TRx0237 250 mg/day
- Where
- 121 sites in United States, Australia and 14 more
- Volunteers
- 891 people
- Sponsor
- TauRx Therapeutics Ltd
Alzheimer's Disease, Dementia
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance.
- Conditions
- Alzheimer's Disease, Dementia, Memory Loss, Cognitive Impairment
- Trial name
- NCT01354691
- Testing
- ladostigil hemitartrate
- Where
- 19 sites in Austria, Croatia and 3 more
- Volunteers
- 200 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Alzheimer Disease
An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type
Objectives: The objective of this study will be to determine the safety, tolerability, drug blood levels, and efficacy of each of three doses of NS 2330 (Tesofensine) given once daily compared with placebo in patients with mild…
- Trial name
- NCT00153010
- Testing
- NS 2330 (Tesofensine)
- Where
- 87 sites in United States, Canada
- Volunteers
- 430 people
- Sponsor
- Boehringer Ingelheim
Alzheimer Disease
Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease
This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD.
- Trial name
- NCT03522129
- Testing
- CT1812
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Cognition Therapeutics
Alzheimer Disease, Caregivers
Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer's Disease
A unique multinational study was conducted simultaneously in the USA, England and Australia. The goals of the study were to answer two questions: Does psychosocial support for the family enhance the effectiveness of drug…
- Trial name
- NCT00467766
- Testing
- Psychosocial information, counseling, and support, Donepezil (Aricept)
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 300 people
- Sponsor
- Pfizer
Alzheimer's Disease
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease to evaluate the safety and tolerability of oral CT1812…
- Trial name
- NCT02907567
- Testing
- CT1812
- Where
- 4 sites in Australia
- Volunteers
- 19 people
- Sponsor
- Cognition Therapeutics
Alzheimer Disease
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo.
- Trial name
- NCT00676143
- Testing
- bapineuzumab
- Where
- 288 sites in United States, Argentina and 22 more
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Alzheimer Disease
Study of the Effect of SR57667B in Patients With Alzheimer's Disease
The primary objective is to demonstrate that SR57667B at the dose of 4 mg/day, in comparison to placebo, decreases the decline in cognitive performance and the global clinical decline over 1 year in patients with mild to moderate…
- Trial name
- NCT00285025
- Testing
- SR57667B
- Volunteers
- 500 people
- Sponsor
- Sanofi
Alzheimer's Disease
Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease
The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for Alzheimer's disease.
- Trial name
- NCT00555204
- Testing
- ABT-089
- Where
- 42 sites in United States
- Volunteers
- 337 people
- Sponsor
- Abbott
Alzheimer's Disease
A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
The study is designed to investigate the safety and efficacy of SB-742457 when added to stable donepezil treatment in subjects with mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00710684
- Testing
- SB-742457 15mg, SB-742457 35mg, donepezil 5-10mg
- Where
- 102 sites in United States, Argentina and 7 more
- Volunteers
- 682 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease, Dementia
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or…
- Trial name
- NCT01969123
- Testing
- Drug: EVP-6124
- Where
- 82 sites in United States, Australia and 10 more
- Volunteers
- 474 people
- Sponsor
- FORUM Pharmaceuticals Inc
Alzheimer Disease, Cognitive Dysfunction
Effect of Scene-Based Training on Cognitive Function in Patients With Alzheimer's Disease
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, including impairments in orientation, memory, and daily functioning.
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Mild Cognitive Impairment
- Trial name
- NCT07548073
- Testing
- Scenario-Based Reenactment Training, Usual Care
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Zhejiang Provincial Tongde Hospital
Osteoporosis
Effect of Acetylcholinesterase Inhibitors on Bone Metabolism
People with Alzheimer's disease are at an increased risk of bone fracture. Some studies have shown that those taking donepezil have a lower rate of bone fractures, but the reasons for this are unknown.
- Trial name
- NCT06041789
- Testing
- Donepezil, Memantine
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Duke University